Filing Analysis
Sutro Biopharma, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2026, and provided an updated corporate presentation.
π Key Facts
- Report date: August 12, 2026
- Quarterly earnings release for the quarter ended June 30, 2026 (Item 2.02)
- Updated corporate presentation released via Regulation FD disclosure (Item 7.01)
Sutro Biopharma, Inc. has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)) after its stock maintained a closing bid price of at least $1.00 for 10 consecutive business days as of December 16, 2025.
π© Red Flags
- Historical price volatility/decline (stock was previously in danger of delisting due to falling below $1.00).
π Key Facts
- The Company regained compliance with Nasdaq Listing Rule 5450(a)(1) on December 16, 2025.
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- The previous non-compliance notice was issued on June 20, 2025, due to the stock falling below $1.00 for 30 consecutive business days.
- Nasdaq has confirmed that the listing matter is now closed.
Sutro Biopharma, Inc. is implementing a 1-for-10 reverse stock split effective December 3, 2025. This action reduces the total outstanding shares from approximately 85.19 million to approximately 8.52 million.
π© Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or signal liquidity concerns).
π Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date/time: December 3, 2025, at 12:01 am Eastern Time.
- Pre-split outstanding shares: ~85,193,912.
- Post-split outstanding shares: ~8,519,392.
- New CUSIP number: 869367201.
- Fractional shares will be rounded up to the nearest whole share.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarterly period ended September 30, 2025.
π Key Facts
- The filing was made on November 6, 2025.
- The report pertains to the quarter ended September 30, 2025.
- The company is listed on the Nasdaq Global Market under ticker STRO.
Sutro Biopharma announced a significant corporate restructuring involving a workforce reduction of approximately one-third to prioritize its ADC programs. The company expects this move to extend its cash runway into mid-2027, despite incurring $4.1M-$4.3M in immediate restructuring costs.
π© Red Flags
- Significant workforce reduction (one-third of staff) indicates distress or aggressive pivot in operations.
- Immediate cash outflow of $4.1M-$4.3M for restructuring costs during a period of prioritization.
- Heavy reliance on 'expected near-term milestone payments' to maintain liquidity.
π Key Facts
- Workforce reduction of approximately one-third of total employees.
- Restructuring costs estimated between $4.1 million and $4.3 million, mostly payable in Q4 2025.
- Objective is to extend cash runway into at least mid-2027 via cost savings and expected milestone payments.
- Focusing resources on three preclinical ADC programs and R&D collaborations.
- Clinical data for STRO-004 (Tissue Factor-targeting exatecan ADC) is anticipated in 2026.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal notification of the release of quarterly earnings data.
π Key Facts
- The company reported financial results for the fiscal quarter ending June 30, 2025.
- The announcement was made on August 7, 2025.
- Financial results were released via a press release attached as Exhibit 99.1.
Sutro Biopharma, Inc. received a notice from NASDAQ regarding non-compliance with the $1.00 minimum bid price requirement for continued listing on the NASDAQ Global Market. The company has until December 17, 2025, to regain compliance or face potential delisting.
π© Red Flags
- Delisting notice from NASDAQ
- Failure to maintain minimum bid price requirement
- Explicit mention of an impending reverse stock split as a remediation strategy
π Key Facts
- Received written notice from NASDAQ on June 20, 2025.
- Non-compliance is due to failure to meet the $1.00 minimum bid price requirement (Listing Rule 5450(a)(1)).
- The company has a 180-day grace period until December 17, 2025, to regain compliance.
- To regain compliance, the stock must close at or above $1.00 for ten consecutive business days during the period.
- The company explicitly stated it plans to implement a reverse stock split if necessary before the deadline.
Sutro Biopharma, Inc. held its 2025 Annual Meeting of Stockholders on June 6, 2025, where shareholders approved a proposal to amend the Certificate of Incorporation to effect a reverse stock split with a ratio between 1-for-5 and 1-for-25.
π© Red Flags
- Approval of a reverse stock split (ratio up to 1-for-25) is often used to regain compliance with minimum bid price requirements for Nasdaq listing.
- High number of 'Withheld' or 'Against' votes on director elections suggests potential shareholder dissatisfaction with governance.
π Key Facts
- Annual Meeting held on June 6, 2025.
- Shareholders approved the election of three Class I directors: Heidi Hunter, Jon Wigginton, and Michael Dybbs.
- Ratification of Ernst & Young LLP as independent auditor for fiscal year ending Dec 31, 2025 was approved (67.4M votes 'For').
- Shareholders approved a non-binding advisory vote on executive compensation ('Say-on-Pay').
- Shareholders approved an amendment to the Charter to allow a reverse stock split ratio between 1-for-5 and 1-for-25, at the Board's discretion.
Sutro Biopharma, Inc. announced the appointment of Gregory K. Chow as Chief Financial Officer (CFO), principal financial officer, and principal accounting officer, effective June 2, 2025.
π Key Facts
- Gregory K. Chow appointed as CFO, effective June 2, 2025.
- Annual base salary is set at $475,000 with a target annual cash bonus of 40% of base salary.
- Equity compensation includes an option to purchase up to 275,000 shares (vesting over 4 years) and 100,000 restricted stock units (vesting over 4 years).
- Severance package includes 15 months of base salary and COBRA premiums if terminated without cause or for good reason.
- Mr. Chow has extensive biotech finance experience, previously serving at NodThera, Freenome Holdings, Frontier Medicines Corp., and Aptose Biosciences Inc.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2025.
π Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations and Financial Condition).
- Reporting period: Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The company's ticker is STRO, listed on the Nasdaq Global Market.
Sutro Biopharma, Inc. announced that Dr. John Freund will not stand for re-election to the Board of Directors at the upcoming Annual Meeting on June 6, 2025. The departure is characterized as a non-disagreement with company operations or policies.
π Key Facts
- Dr. John Freund has served on the Board since 2014.
- His term will expire following the Annual Meeting of Shareholders scheduled for June 6, 2025.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
- Dr. Freund will remain engaged as a consultant to management.
Sutro Biopharma is undergoing a massive corporate restructuring involving a 50% workforce reduction, the exit of its internal GMP manufacturing facility, and the deprioritization of its luvelta (STRO-002) program. This strategic pivot is accompanied by a complete overhaul of the executive leadership team.
π© Red Flags
- Massive workforce reduction (50%) indicating significant distress or extreme pivot.
- Significant cash outflow ($40M-$45M) for restructuring and severance in a micro-cap context.
- Complete turnover of the C-suite (CEO, CFO, CMO departing).
- Exit from internal manufacturing facilities suggests a shift to a leaner, asset-light model likely driven by capital constraints.
π Key Facts
- Company plans to reduce its workforce by approximately 50%.
- Total restructuring costs estimated at $40 million to $45 million, with most due in 2025.
- Deprioritizing luvelta (STRO-002) activities; will continue to explore outlicensing opportunities.
- Exiting internal GMP manufacturing facility by year-end 2025.
- CEO William J. Newell is departing; Jane Chung appointed as new CEO.
- CFO Edward C. Albini and CMO Dr. Anne Borgman are also departing the company.
- Focusing resources on three preclinical ADC programs, specifically STRO 004 (targeting Tissue Factor), expected in clinic H2 2025.
Sutro Biopharma announced topline results from the dose-optimization portion (Part 1) of its REFRΞ±ME-O1 clinical trial for luvelta, an ADC targeting platinum-resistant ovarian cancer. The data showed a 32% objective response rate and a 96% disease control rate in the 5.2 mg/kg dosing group.
π© Red Flags
- Clinical stage risk: Results are from a small dose-optimization cohort (N=25), which may not fully predict outcomes in the larger Part 2 registrational trial.
- Safety signal: 32% incidence of Grade 3 or higher neutropenia.
π Key Facts
- Trial: REFRΞ±ME-O1 (Part 1) dose-optimization portion for luvelta in platinum-resistant ovarian cancer (PROC).
- Objective Response Rate (ORR): 32% in the 5.2 mg/kg group (N=25).
- Disease Control Rate (DCR): 96% in the 5.2 mg/kg group.
- Safety: Grade 3 or higher neutropenia occurred in 32% of patients; no febrile neutropenia reported.
- Patient Profile: Approximately 50% of treated patients were ineligible for currently approved FRΞ±-targeting ADCs; 88% had prior bevacizumab treatment.
- Next Steps: REFRΞ±ME-O1 (Part 2) is an ongoing global registrational trial enrolling ~500 patients comparing luvelta to investigator's choice of chemotherapy.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
π Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release regarding financial results (Exhibit 99.1)
- Signed by Edward Albini, Chief Financial Officer
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
π Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Sutro Biopharma, Inc. announced the appointment of Sukhi Jagpal to its Board of Directors as a Class III director and member of the Audit Committee.
π Key Facts
- Sukhi Jagpal appointed as Class III director effective August 8, 2024.
- Jagpal will join the Audit Committee effective August 15, 2024.
- Compensation includes a pro rata portion of a $40,000 annual director retainer and a $10,000 annual Audit Committee retainer.
- Granted stock option for 35,000 shares vesting monthly over three years.
- Granted stock option for 28,959 shares vesting monthly until the 2025 annual meeting of shareholders.
Sutro Biopharma, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of two Class III directors and the ratification of Ernst & Young LLP as the company's independent auditor.
π Key Facts
- Held 2024 Annual Meeting of Stockholders on June 6, 2024.
- Elected Joseph M. Lobacki to a three-year term (expires 2027).
- Elected Daniel H. Petree to a three-year term (expires 2027).
- Ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approved non-binding advisory compensation ('Say on Pay') for named executive officers.
- Approved amendment to the 2018 Employee Stock Purchase Plan (ESPP) to increase share limits and make clarifying revisions.
Sutro Biopharma, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2024.
π Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 13, 2024.
- The financial results were released via press release attached as Exhibit 99.1.
Sutro Biopharma, Inc. entered into an underwriting agreement to issue and sell 14,478,764 shares of common stock at $5.18 per share. The offering aims to raise approximately $75 million in gross proceeds for general corporate purposes, including R&D and clinical development.
π© Red Flags
- Significant dilution for existing shareholders due to the issuance of over 14 million new shares.
π Key Facts
- Offering size: 14,478,764 shares of common stock.
- Offering price: $5.18 per share.
- Estimated gross proceeds: Approximately $75.0 million.
- Underwriter: BofA Securities, Inc.
- Expected closing date: April 4, 2024.
- Use of proceeds: Research, clinical/process development, manufacturing, working capital, and potential acquisitions.
Sutro Biopharma entered into an exclusive license agreement with Ipsen Pharma SAS for the development and commercialization of STRO-003. The deal includes a significant upfront cash payment and a strategic equity investment from an Ipsen affiliate.
π© Red Flags
- Ipsen retains the right to terminate the agreement for convenience with 60 days' notice, which limits Sutro's long-term control over the asset.
- The equity issuance is a private placement (unregistered sale) involving an affiliate of the licensee.
π Key Facts
- Exclusive License Agreement signed March 29, 2024, with Ipsen Pharma SAS regarding STRO-003.
- $50 million upfront license fee payable within 30 days of the effective date.
- Ipsen Biopharmaceuticals, Inc. (affiliate) to purchase 4,827,373 shares for $25 million at a 17% premium to the 20-day VWAP.
- Potential milestone payments: up to $7 million cash and $10 million in additional shares upon specific developmental milestones.
- Total potential future value includes up to $447 million in development/regulatory milestones and up to $360 million in sales milestones.
- Royalty payments range from low double-digit to mid-teen percentages of annual net sales.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of their annual earnings press release.
π Key Facts
- Report date: March 25, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the official press release of financial results.
- Information under Item 2.02 is furnished but not considered 'filed' for liability purposes.
Sutro Biopharma, Inc. has filed a prospectus supplement to its existing 2023 Form S-3 shelf registration statement to increase the aggregate dollar amount of shares available for sale by $100,000,000.
π© Red Flags
- Significant increase in share availability ($100M) suggests a need for immediate liquidity or capital to fund operations, common in pre-revenue biotech firms.
π Key Facts
- Increased the aggregate dollar amount of shares available under the Sales Agreement by $100,000,000 via a prospectus supplement filed on February 9, 2024.
- The company has previously sold an aggregate of $70,725,847.70 in shares through its 2021 Form S-3 shelf registration statement.
- As of the filing date, remaining capacity under the 2021 S-3 is $29,274,152.30; the new supplement adds $100,000,000 in capacity.
- The sales agent for these transactions is Jefferies LLC.
Sutro Biopharma reported its preliminary cash position as of December 31, 2023, and provided clinical updates for its lead ADC candidate, luvelta. The company maintains a significant cash runway extending into the second half of 2025.
π© Red Flags
- Financial data is preliminary, unaudited, and subject to change upon final audit.
π Key Facts
- Reported approximately $333 million in cash, cash equivalents, and marketable securities as of Dec 31, 2023.
- Held ~0.7 million shares of Vaxcyte common stock with an estimated fair value of ~$42 million.
- Cash runway is expected to fund operations into the second half of 2025.
- Luvelta REFRΞ±ME-O1 trial (ovarian cancer) expects Part 1 completion in H1 2024.
- Planned IND submission for non-small cell lung cancer (NSCLC) in H1 2024.